Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting.
Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Hochbergerstrasse 60c, Basel,basel-Town 4057,switzerland
- Phone
- +41 61 638 23 60
- IN****@****MEB.COM
- Industry
- Biotechnology
- Website
- versameb.com
- HQ
- Basel, Basel-Town
Versameb Ag Questions
Versameb Ag's helpline number is +41 61 638 23 60
Versameb Ag's website is versameb.com
Versameb Ag's LinkedIn profile is https://ch.linkedin.com/company/versameb
Versameb Ag has
8 employees.
View email and phone details for 8
employees at Versameb Ag.
Versameb Ag's industry is
Biotechnology
Versameb Ag's top competitors are
Alentis Therapeutics,
Cellestia Biotech,
Bright Peak Therapeutics,
Tolremo Therapeutics,
Bioversys Ag,
Nbe-Therapeutics Ag,
Haya Therapeutics,
Araris Biotech Ag,
Anaveon Ag,
T3 Pharmaceuticals Ag.
Versameb Ag's support email address is INFO@VERSAMEB.COM
Versameb Ag's categories are Biotechnology
Versameb Ag's founding year is 2017
